Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPER: Triple Therapy (V-L-D) vs Lucentis Monotherapy for AMD
NCT00457678Phase 2Withdrawn
- Sponsor
- Vitreous Retina Macula Consultants of New York
- Start
- Jan 2007
- Primary completion
- Dec 2007
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
01
Overview
Phase 2, randomised, single-blind trial of verteporfin and dexamethasone in age-related macular degeneration (AMD), sponsored by Vitreous Retina Macula Consultants of New York. Primary endpoint: Visual Acuity at 12 months. Planned start Jan 2007; status: withdrawn.
02
Drugs
verteporfindexamethasone
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00457678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457678.